Founded in 1404, the University of Torino (UniTo) is one of the largest Italian Universities, with over 81.000 students, 6.2% of which of non-Italian citizenship, around 4.000 employees (academic, administrative and technical staff), more than 1.300 PhD students and more than 580 research fellows. Research and training are performed in 27 Departments, encompassing all scientific disciplines except engineering and architecture. The University activities are carried out in more than 100 venues in the whole Region, including 71 labs and infrastructures and 22 libraries with full access to the web, the Botanical Garden and a number of University Museums.
According to the ARWU international ranking, in 2022 UniTo ranked as the 5th university in Italy and among the top 300 universities out of 1.200 worldwide.
Today, the University of Torino offers over 150 undergraduate and graduate degree programs in almost every field of study involving about 5,000 international students (a.y. 2022-2023). A growing number of programs are taught in English, and Italian language tuition is available for incoming students. Doctoral school provides 54 doctoral programs.
Role in the project
UniTo is the lead Institution of work package 4 (WP4) – Impact of EDCs and their mixtures on progression of MASLD, that represents the clinical component of the EDC-MASLD programme. The specific objective of WP4 is to characterize the impact of environmental exposure to EDCs on the degree of liver damage in MASLD and MASLD-related outcomes in prospective study settings. To achieve this goal, new multi-omics data will be generated in clinical cohorts of patients histologically characterised for MASLD from the in the European NAFLD Registry (cross-sectional and prospective), in order to investigate the association between environmental toxicants (potential EDCs) and progressive stages of MASLD, including related complications such as HCC, T2D, and CVD. Among multi-omics, UniTo will perform targeted steroidomics analysis on the Orbitrap Fusion high-resolution mass spectrometer. In addition, UniTo will be responsible for the maintenance and longitudinal follow-up of patients included in the European NAFLD Registry as well as for the recruitment of new patients across the full spectrum of MASLD.
